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Abstract
Renal involvement by sarcoidosis in native and transplanted kidneys classically presents as non caseating granulomatous
interstitial nephritis. However, the incidence of sarcoidosis in native and transplant kidney biopsies, its frequency as a cause
of end stage renal disease and its recurrence in renal allograft are not well defined, which prompted this study. The
electronic medical records and the pathology findings in native and transplant kidney biopsies reviewed at the Johns
Hopkins Hospital from 1/1/2000 to 6/30/2011 were searched. A total of 51 patients with a diagnosis of sarcoidosis and renal
abnormalities requiring a native kidney biopsy were identified. Granulomatous interstitial nephritis, consistent with renal
sarcoidosis was identified in kidney biopsies from 19 of these subjects (37%). This is equivalent to a frequency of 0.18% of
this diagnosis in a total of 10,023 biopsies from native kidney reviewed at our institution. Follow-up information was
available in 10 patients with biopsy-proven renal sarcoidosis: 6 responded to treatment with prednisone, one progressed to
end stage renal disease. Renal sarcoidosis was the primary cause of end stage renal disease in only 2 out of 2,331 transplants
performed. Only one biopsy-proven recurrence of sarcoidosis granulomatous interstitial nephritis was identified.
Conclusions: Renal involvement by sarcoidosis in the form of granulomatous interstitial nephritis was a rare finding in
biopsies from native kidneys reviewed at our center, and was found to be a rare cause of end stage renal disease. However,
our observations indicate that recurrence of sarcoid granulomatous inflammation may occur in the transplanted kidney of
patients with sarcoidosis as the original kidney disease.
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Introduction
Sarcoidosis is a systemic disorder of unclear etiology, which
results from an abnormal cell-mediated immune reaction, and is
characterized by non caseating granulomatous inflammation with
epithelioid cells and multinucleated giant cells. Sarcoidosis affects
individuals mostly in their third or fourth decades. Its incidence
has been reported to be as high as 40 cases per 100,000 in Europe
[1]. In the US population sarcoidosis is about three times more
common in blacks than in white [2].
Sarcoidosis most commonly affects the lungs, but multiple
organs such as the central nervous system, liver, heart, skin, and
kidney can be involved.
Sarcoid involvement of the native kidney, in the form of
granulomatous tubulointerstitial nephritis, is unusual, but its
frequency is unclear, with estimates up to 30% of patients with
this disorder in earlier studies [3] and as low as 0.7% in more
recent reports [4,5]. It is also not clear how often renal sarcoidosis
leads to end stage renal disease (ESRD).
Only a few cases of recurrent sarcoidosis with granulomatous
inflammation in the transplanted kidney have been described
[6,7,8,9]. A multicenter study from France [10], reported
recurrence in the transplanted kidney of 3 recipients with
sarcoidosis as the original disease.
The main objectives of this study were to evaluate the incidence
of renal sarcoidosis in patients with diagnosis of systemic
sarcoidosis and with kidney abnormalities requiring a kidney
biopsies, its frequency as a cause of ESRD in transplant recipients,
the incidence of recurrence of renal sarcoidosis in transplanted
kidneys, and the overall frequency of interstitial granulomatous
sarcoidosis in native kidney biopsies. To this end we searched the
electronic medical records and the archives of the Department of
Pathology at the Johns Hopkins Hospital over a period between
2000 and 2011. Our findings are described and discussed here.
The study was approved by the John Hopkins Institutional
Review Board (protocol NA_00001141, which includes approval
by Johns Hopkins IRB of a waiver of consent for subjects whose
clinical information was used for studies covered by this protocol).
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Methods
Patients
Computerized records were searched to identify kidney biopsies
reviewed in the Department of Pathology at Johns Hopkins
University from 1/1/2000 to 6/30/2011.
The demographic and clinical information provided at time of
biopsy and afterwards were recorded, when available, for subjects
with native kidney biopsies and for those with renal graft biopsies,
and included: age at biopsy, gender, race, relevant past medical
history, serum creatinine (mg/dL), urinalysis, pertinent serology
tests, clinical course and follow up (when documented).
GFR was estimated according to the MDRD calculation [11].
Biopsies
Native kidney biopsies were processed for light microscopy,
immunofluorescence and electron microscopy. Special stains of
sections from paraffin embedded tissue such as Grocott methena-
mine silver, and stain for Acid Fast Bacilli were performed to rule
out fungi and mycobacteria. Kidney allograft biopsies were stained
for C4d as previously described [12,13] and graded for rejection
according to the Banff classification [14,15].
Biopsies from patients with histologic findings of granulomatous
inflammation were re-examined for this study by one nephro-
pathologist (SMB).
Statistical analysis
Continuous variables with normal distribution were analyzed by
un-paired, two-tailed Student’s T test, with P#0.05 as indicative of
significant difference. Chi square test or Mann-Whitney test were
used for categorical variables. Statistical analyses were performed
with GraphPad Prism software, version 5 (GraphPad Software,
Inc., San Diego, CA, USA).
Results
A total of 14,306 kidney biopsies were reviewed in the
Department of Pathology at the Johns Hopkins Hospital between
January 2000 to June 2011, of which 10,023 were from native
kidneys, and 4,283 from kidney allografts.
A diagnosis of sarcoidosis was reported in the medical history of
52 patients who had renal/urinary abnormalities requiring native
or allograft kidney biopsy, with a total of 57 kidney biopsies
performed on these subjects. The demographic data in Table 1
show that age ranged from 20 to 80 years at time of kidney biopsy,
there was a higher proportion of females (57%), and a higher
number of black individuals (73%).
In 51 patients with a history of sarcoidosis a biopsy of the native
kidney was performed, the pathologic findings in these biopsies are
listed in Table 2.
Interstitial nephritis was the main diagnosis in approximately
half of these patients (27 cases, granulomatous and non
granulomatous), the remaining patients showed renal lesions
without no obvious association with sarcoidosis. Granulomatous
interstitial nephritis as the manifestation of renal sarcoidosis was
identified in 19 of these biopsies, in which infections, drug
reactions, and Wegener’ granulomatosis could be ruled out. This is
equivalent to a frequency of 0.18% of this diagnosis in a total of
10,023 biopsies from native kidney reviewed at our institution.
There were no distinct demographic or clinical features in those
patients with granulomatous interstitial involvement by sarcoido-
sis, compared to those with a history of sarcoidosis but without
renal granulomatous inflammation.
The 19 patients with a biopsy-proven granulomatous sarcoidosis
in the native kidney had abnormal serum creatinine:
3.9662.35 mg/dl (average 6 SD; range 1.9–9 mg/dl). Protein-
uria was known to be present in 12 patients, ranging from trace to
2.5 g/24 hours, it was quantified in 8 patients with an average of
0.9460.65 g/24 hours. Hypercalcemia was present in 7 of 19
patients but only 3 had evidence of microcalcifications in the
kidney biopsy.
Histologic evaluation of these 19 biopsies showed that the non
caseating granulomatous inflammation was usually extensive,
involving more than 50% of the kidney sample in 16 biopsies
(figure 1). Most biopsies showed only rare eosinophils, and only 3
biopsies showed eosinophils present in more than one cluster with
.4 eosinophils per high power field, usually embedded in the
granulomatous inflammation. There was more than 50% global
glomerulosclerosis in 7 biopsies. Tubulointerstitial scarring
involving more than 50% of the sampled kidney was identified
in 12 biopsies.
Only limited data on follow up were available in 10 patients
with renal granulomatous sarcoidosis in the native kidney
(Table 3). The patients with this lesion were treated with doses
of prednisone ranging from 25 to 80 mg/day, tapered or
suspended within one to three years, with general improvement
of renal function, although in 4 patients with more than 50%
tubulointerstitial scarring serum creatinine did not return to
previous baseline level, and one patient progressed to ESRD
requiring dialysis.
In order to estimate how often sarcoidosis appears as a primary
cause of ESRD in our center we reviewed our transplant database
and the electronic medical records of the transplant recipients
searching for the original renal disease in the native kidney.
From 2000 to the end of 2010, a total of 2,331 patients received
a kidney transplant at the Comprehensive Transplant Program at




Age at time of biopsy 50613
Race: Black/White (N) 31/11 (42)
Hypertension 21
Diabetes 12
Values are presented as Mean 6 SD. (N) indicates the number of patients for whom this information was available.
doi:10.1371/journal.pone.0110778.t001
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the Johns Hopkins Hospital. The immunosuppressive regimen
included induction with either daclizumab or ATG, tacrolimus,
mycophenolate, and steroids. Episodes of cellular rejection (both
clinical and subclinical) with Banff grades of 1A or 1B were treated
with a 3-day pulse of dexamethasone 100 mg/day followed by a
taper. If the Banff score was 2A, 2B, or 3 patients received a 7-day
course of anti-thymocyte globulin. Both clinical and sub-clinical
C4d positive AMR in the presence of DSA was treated with
plasmapheresis/IVIg.
A clinical history of systemic sarcoidosis was recorded for 4
kidney transplant recipients. All had inactive disease at the time of
transplantation. Two had previous history of lung sarcoidosis, but
the cause of ESRD was hypertensive nephrosclerosis. Only two
patients (one black female, and one white female) had sarcoidosis
in lung and kidney, and lost their native kidneys due to renal
sarcoidosis. This suggests that the frequency of sarcoidosis as
primary cause of renal failure leading to ESRD could be estimated
as less than 1 in 1000 in patients who received a transplanted
kidney. Post-transplant, the maintenance immunosuppression may
reduce the risk of recurrence of sarcoidosis in transplant recipients.
Review of the transplant outcome in these 4 patients revealed
that one lost the graft to chronic changes unrelated to sarcoidosis
after 12 years, requiring hemodialysis. Recurrent renal sarcoidosis
was detected in a single patient, a 51 year old Caucasian female
who had been diagnosed with sarcoidosis at the age of 47, with
involvement of the lungs, CNS, and kidney (biopsy-proven) by
granulomatous disease, treated with Prednisone 5 mg, and
Azathioprine 75 mg daily, and quiescent at the time of transplan-
tation. She received a pre-emptive, HLA-compatible live donor
kidney, requiring no pre-transplant desensitization, and with
immediate function, resulting in a stable serum creatinine of
1.2 mg/dL (eGFR 48 mL/min/1.73 m2). Induction immunosup-
pression consisted of basiliximab, followed by post-transplant
standard maintenance immunosuppressive regimen with Predni-
sone 5 mg once a day, Tacrolimus 0.5 mg twice a day and
Mycophenolate 500 mg twice a day. Recurrence was discovered
in an incidental kidney biopsy performed at 17 months post-
transplant during a hernia surgical repair, with no evidence of
active sarcoidosis, no urinary infections, and stable eGFR 47 mL/
min/1.73 m2. The biopsy showed tubulointerstitial granulomatous
Table 2. Main histological diagnoses in 56 native kidney biopsies from 51 patients carrying a diagnosis of sarcoidosis.
Diagnosis N
Granulomatous interstitial nephritis* 19
Interstitial nephritis without granuloma 8
Diabetic nephropathy 7
Focal Segmental Glomerulosclerosis 6
Chronic/Advanced sclerosing changes** 6
Immune complex mediated glomerulonephritis 3
Acute tubular injury 3
Amyloid 1
Membranous glomerulopathy 1
Thin glomerular basement membrane disease 1
Non specific changes 1
*A diagnosis of granulomatous interstitial nephritis consistent with renal sarcoidosis was rendered when other potential differential diagnoses (drug reactions, bacterial,
mycobacterial and fungal infections, de novo or recurrent Wegener’ granulomatosis, foreign body reaction) could be excluded.
**This category includes: Severe global glomerulosclerosis; Tubulointerstitial scarring; Hypertensive nephrosclerosis; Transplant glomerulopathy with tubulointerstitial
scarring.
doi:10.1371/journal.pone.0110778.t002
Figure 1. Moderate to severe interstitial inflammation with non
caseating granuloma in renal sarcoidosis (A). Multinucleated cells in
granulomatous inflammatory infiltrate in renal sarcoidosis (B).
doi:10.1371/journal.pone.0110778.g001
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inflammation, with negative C4d, and was interpreted as most
consistent with recurrent sarcoidosis, although it was not possible
to completely rule out a component of cell mediated rejection
(Banff score: g0, i3, t3, v0, ah0, cg0, ci3, ct3, cv1, mm2, ptc
undetermined, C4d0, ti3). She was treated for 5 days with
Prednisone 80 mg per day, eventually tapered to a maintenance
dose of 15 mg per day, while continuing Mycophenolate 500 mg
three times per day, and Tacrolimus 1 mg two times per day. The
increased immunosuppression was complicated by Herpes virus
esophagiitis, and Cytomegalovirus infection, resolved with antivi-
ral treatment, and resolution of infection (eGFR of 34 mL/min/
1.73 m2 six months later).
Discussion
The main objectives of this study were to evaluate the incidence
of granulomatous tubulointerstitial nephritis in patients with a
diagnosis of sarcoidosis; the overall frequency of this diagnosis in
native kidney biopsies; the frequency of sarcoidosis as the primary
kidney disease leading to ESRD; the incidence of recurrence of
renal sarcoidosis in transplanted kidneys.
We found that among patients with a clinical history of
sarcoidosis and evidence of renal disease requiring a native kidney
biopsy 37% had granulomatous interstitial nephritis.
The demographic characteristics of our cohort of patients with a
history of sarcoidosis showed a prevalence of female gender (57%)
matching previously observed gender distribution [16], and a
significantly higher proportion of black individuals (73%), reflect-
ing estimates that in the US population sarcoidosis is three times
more common in blacks (35.5 per 100,000) than in whites (10.0
per 100,000) [2].
Clinical information available on these patients shows that
hypercalcemia was present in 7 (21%) of patients with a history of
sarcoidosis, similar to previous estimates [17]. However only 3 of
these individuals showed sparse microcalcifications in their kidney
biopsies.
Granulomatous interstitial nephritis by itself is rare in biopsies
from both native kidneys [18,19], and from transplanted kidneys
[20], with an overall estimated occurrence of,1% biopsies. In our
center the incidence of this pathologic finding is also very low
0.48% (unpublished observation), consistent with previous reports.
In this study, the frequency of granulomatous inflammation
ascribable to sarcoidosis in native kidney biopsies appears even
lower: 0.18% of 10,023 diagnostic biopsies from native kidney
reviewed at our institution.
Given the limited follow up information on the patients with
biopsy-proven renal granulomatous sarcoidosis in the native
kidney it is not possible to comment on specific characteristics
that may influence the course of this renal lesion, except that
tubulointerstitial scarring may indicate poor prognosis.
At time of diagnosis serum creatinine was noted to be abnormal
in most of these patients, some presenting with acute kidney injury.
In some, the possibility that a component of tubulointerstitial
damage could be associated with pharmacologic treatment was
entertained in the differential diagnosis. Such possibility should be
considered in the therapeutic approach in these cases.
It is not clear how many patients with renal sarcoidosis progress
to end stage renal disease. In this study, 3 or 5% of a total of 55
patients (including 51 patients with native kidney biopsies and 4
transplant recipients) with a diagnosis of systemic sarcoidosis
progressed to ESRD, slightly higher but similar to an estimated
2% reported in a French cohort [21].
Recurrence of renal sarcoidosis post transplantation was
documented in only one out of two transplant recipients with
ESRD due to sarcoidosis at our center in the past ten years, and
was detected 17 months after transplant as an asymptomatic lesion
in an incidental biopsy.
Aside from few case reports, the recurrence of sarcoidosis in
kidney transplant recipients was examined in a recent, retrospec-
tive, multicenter study from France, describing 10 patients with
ESRD due to sarcoidosis, who received a kidney transplant [10].
Of these, 3 patients developed granulomatous tubulointerstitial
nephritis in the renal graft, representing a 30% recurrence of renal
sarcoidosis. The recurrence occurred within 18 months post-
transplantation, while the patients were receiving a maintenance
immunosuppression regimen including 5 mg prednisone per day.
Treatment for recurrence consisted of increasing the corticoste-
roids dose from 0.3 to 0.5 mg/kg/day for 1 month, followed by a
progressive tapering of the dose. The outcome was resolution with
improved GFR for one patient, one patient progressed to renal
graft failure, and the third patient died from a pulmonary
embolism. Perhaps follow-up biopsies at one or two years post
transplant may be indicated in to rule out ‘‘subclinical’’ recurrence
in transplant recipient with renal granulomatous sarcoidosis as the
original disease.




Age years 49614 (50)
Serum Creatinine, mg/dl
Baseline 1.660.5 (1.4)
At biopsy 4.362.6 (3.0)
At last FU 2.461.6 (1.8)
Prednisone mg/day 50617 (50)
Years of treatment 1.560.8 (1.0)
Total FU years 3.063.1 (1.7)
ESRD 1
Data are shown as Mean 6 SD (Median).
doi:10.1371/journal.pone.0110778.t003
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The clinical management and immunosuppression of these rare
patients may be challenging. The available literature suggests that
steroids should be maintained in the therapeutic regimen post-
transplantation to prevent recurrence of disease [7,8,9]. Recently,
monoclonal antibodies inhibiting interleukin 12, interleukin 23,
and tumor necrosis factor alpha have been tested in patients with
lung and/or skin sarcoidosis, however, the superiority of this
treatment compared with steroids is unclear [22]. The recurrence
in our patient was treated with an increased dose of steroids with
subsequent decrease of her serum creatinine toward her baseline
level. Over-immunosuppression should be avoided to reduce the
risk of infection. Over-immunosuppression may have played a role
in the lethal fungal infection of the pediatric patient reported by
Vargas et al.[9]. The post-biopsy course of our index case suggests
that development of CMV and HSV was temporally associated
with the escalation in her steroids and other maintenance
immunosuppression, and cause and effect relationship seems
likely.
In summary, our study indicates that less than 1% of patients
with renal abnormalities requiring a native kidney biopsy have a
clinical history of sarcoidosis. Our observations on kidney biopsies
suggest that in patients with history of sarcoidosis and renal
dysfunction about one third shows pathologic manifestation of
renal involvement by sarcoidosis as interstitial nephritis with
granulomatous inflammation. Although renal involvement by
sarcoid granulomatous interstitial nephritis is a rare primary cause
of ESRD in transplant recipients, it can recur in the renal allograft.
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